Bionano Genomics BNGO just pulled back the curtain on its fourth-quarter results, and the message is clear: the company is getting leaner while its technology goes deeper into the clinical mainstream.
The average one-year price target for Bionano Genomics (NasdaqCM:BNGO) has been revised to $5.61 / share. This is a decrease of 26.67% from the prior estimate of $7.65 dated February 21, 2026. The ...
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ...
The critics of Bionano (NASDAQ:BNGO) stock are ignoring and/or severely underestimating developments involving its DNA mapping tool, Saphyr. Source: Natali_ Mis/ShutterStock.com Specifically, there is ...
Detailed price information for Bionano Genomics Inc (BNGO-Q) from The Globe and Mail including charting and trades.
Detailed price information for Bionano Genomics Inc (BNGO-Q) from The Globe and Mail including charting and trades.
Bionano Genomics, Inc. reports earnings inline with expectations. Reported EPS is $-2.475 EPS, expectations were $-2.475. Operator: Good day, and welcome to the Bionano Genomics, Inc. Fourth Quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results